Abstract
The need of using chemically modified siRNA agents for gene silencing continuously increasing as appropriate chemical modification improves their specificity, nuclease stability, potency, and in vivo cellular delivery. The future success of RNAi technology also depends on identifying drug carriers that are non-toxic and tissue-specific in directing the RNAi agents to the desired locations in a cost effective fashion. This review will cover recently reported chemically modified siRNA agents for improving specificity and potency of mRNA knockdown, their nuclease stability, cellular uptake and improved biodistribution. In addition to the chemical modifications and their biological impact, this review also focuses on the in vivo RNAi delivery techniques.
Keywords: Chemical modification, siRNA, RNA interference, RNAi agents, Gene-silencing, miRNA, In vivo RNAi
Current Bioactive Compounds
Title: Chemical Modifications of Synthetic RNAi Agents and in vivo Delivery Techniques
Volume: 4 Issue: 1
Author(s): Anilkumar R. Kore and Lance P. Ford
Affiliation:
Keywords: Chemical modification, siRNA, RNA interference, RNAi agents, Gene-silencing, miRNA, In vivo RNAi
Abstract: The need of using chemically modified siRNA agents for gene silencing continuously increasing as appropriate chemical modification improves their specificity, nuclease stability, potency, and in vivo cellular delivery. The future success of RNAi technology also depends on identifying drug carriers that are non-toxic and tissue-specific in directing the RNAi agents to the desired locations in a cost effective fashion. This review will cover recently reported chemically modified siRNA agents for improving specificity and potency of mRNA knockdown, their nuclease stability, cellular uptake and improved biodistribution. In addition to the chemical modifications and their biological impact, this review also focuses on the in vivo RNAi delivery techniques.
Export Options
About this article
Cite this article as:
Kore R. Anilkumar and Ford P. Lance, Chemical Modifications of Synthetic RNAi Agents and in vivo Delivery Techniques, Current Bioactive Compounds 2008; 4 (1) . https://dx.doi.org/10.2174/157340708784533375
DOI https://dx.doi.org/10.2174/157340708784533375 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Overall Picture of Chemokine Receptors: Basic Research and Drug Development
Current Pharmaceutical Design Cyanidin 3-O-Glucoside Induces the Apoptosis in the Osteosarcoma Cells through Upregulation of the PPARγ and P21: An <i>In Vitro</i> Study
Anti-Cancer Agents in Medicinal Chemistry A Unique Mechanism of Chaperone Action: Heme Regulation of Hap1 Activity Involves Separate Control of Repression and Activation
Protein & Peptide Letters Recent Development in Indole Derivatives as Anticancer Agent: A Mechanistic Approach
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo
Anti-Cancer Agents in Medicinal Chemistry Advances in Translational Pharmacological Investigations in Identifying and Validating Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms
Current Pharmaceutical Design A hypothesis for the role of RECK in angiogenesis
Current Vascular Pharmacology Current Options in the Treatment of Mast Cell Mediator-Related Symptoms in Mastocytosis
Inflammation & Allergy - Drug Targets (Discontinued) Identification of Sets of Cytoskeletal Related and Adhesion-related Coding Region Mutations in the TCGA Melanoma Dataset that Correlate with a Negative Outcome
Current Genomics Extracellular Vesicles as Novel Delivery Tools for Cancer Treatment
Current Cancer Drug Targets <sup>177</sup>Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay
Current Radiopharmaceuticals Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis
Current Pharmaceutical Design Current Perspectives on Cytokines for Anti-retroviral Therapy in AIDS Related B-cell Lymphomas
Current Drug Targets - Infectious Disorders Acetylome Regulation by Sirtuins in the Brain: From Normal Physiology to Aging and Pathology
Current Pharmaceutical Design Lipid Membrane; A Novel Target for Viral and Bacterial Pathogens
Current Drug Targets Sulfonamides and Sulfonylated Derivatives as Anticancer Agents
Current Cancer Drug Targets Drug Carriers in Pharmaceutical Design: Promises and Progress
Current Pharmaceutical Design HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors
Current Topics in Medicinal Chemistry Genetics Talks to Epigenetics? The Interplay Between Sequence Variants and Chromatin Structure
Current Genomics